Over the course of the study 211 patients received treatment.
• Patients infected with genotype 1: 98 percent of previously untreated patients had a sustained virologic response at week 12 after the end of therapy.
• Patients infected with genotype 1: 98 percent of previously treated patients who did not have a sustained virologic response with HCV protease inhibitors had a sustained virologic response at week 12 after the end of therapy.
• Patients infected with genotype 2: 92 percent had a sustained virologic response at week 12.
• Patients infected with genotype 3: 89 percent had a sustained virologic response at week 12.
• The most common adverse events included nausea, headache and fatigue.
More Articles on Gastroenterology:
EndoChoice Launches Study to Demonstrate Clinical Significance of Fuse Endoscopy System
5 Current Treatments for Ulcerative Colitis
Dr. Michael Uzer Joins Sarah Bush Lincoln Health Center
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
